e-Therapeutics plc Holding(s) in Company (0203U)
January 12 2017 - 4:38AM
UK Regulatory
TIDMETX TIDMAV.
RNS Number : 0203U
e-Therapeutics plc
12 January 2017
For filings with the FCA
include the annex
For filings with issuer exclude
the annex
TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES(i)
--------------------------------------------------------------------------------------------------------
1. Identity of the issuer or e-Therapeutics plc
the underlying issuer
of existing shares to which
voting rights are
attached: (ii)
----------------------------------------------------------------- -------------------------------------
2 Reason for the notification (please tick the appropriate
box or boxes):
--------------------------------------------------------------------------------------------------------
An acquisition or disposal of voting rights
-------------------------------------------------------------------- ----------------------------------
An acquisition or disposal of qualifying financial
instruments which may result in the acquisition
of shares already issued to which voting rights
are attached
-------------------------------------------------------------------- ----------------------------------
An acquisition or disposal of instruments with
similar economic effect to qualifying financial
instruments
-------------------------------------------------------------------- ----------------------------------
An event changing the breakdown of voting rights
-------------------------------------------------------------------- ----------------------------------
Other (please
specify):
----------------------------------------------------------- ------- ----------------------------------
3. Full name of person(s) Aviva plc & its subsidiaries
subject to the
notification obligation:
(iii)
------------------------------------------------------------- -----------------------------------------
4. Full name of shareholder(s) Registered Holder:
(if different from 3.):(iv)
BNY Norwich Union Nominees
Limited 3,309,498*
Chase (GA Group) Nominees
Limited 37,607,733*
* denotes direct interest
Chase Nominees Limited 1,625,637
------------------------------------------------------------- -----------------------------------------
5. Date of the transaction 10 January 2017
and date on
which the threshold is
crossed or
reached: (v)
------------------------------------------------------------- -----------------------------------------
6. Date on which issuer 11 January 2017
notified:
------------------------------------------------------------- -----------------------------------------
7. Threshold(s) that is/are 16% to 15% Change at Combined
crossed or Interest Level
reached: (vi, vii)
------------------------------------------------------------- -----------------------------------------
8. Notified details:
--------------------------------------------------------------------------------------------------------------
A: Voting rights attached to shares (viii, ix)
--------------------------------------------------------------------------------------------------------------
Class/type Situation previous Resulting situation after the
of to the triggering triggering transaction
shares transaction
if possible
using
the ISIN
CODE
----------------- ------------------------------ -----------------------------------------------------------
Number Number Number Number of % of voting
of of of shares voting rights (x)
Shares Voting rights
Rights
----------------- ----------------- ----------- ------------- ------------------------ ------------------
Direct Direct Indirect Direct Indirect
(xi) (xii)
----------------- ----------------- ----------- ------------- ----------- ----------- ------- ---------
Ordinary
Shares
GB00B2823H99 44,073,702 44,073,702 42,542,868 40,917,231 1,625,637 15.24% 0.61%
----------------- ----------- ------------- ----------- ----------- ------- ---------
B: Qualifying Financial Instruments
--------------------------------------------------------------------------------------------------------------
Resulting situation after the triggering transaction
--------------------------------------------------------------------------------------------------------------
Type of Expiration Exercise/ Number of voting % of voting
financial date Conversion rights that rights
instrument (xiii) Period (xiv) may be
acquired if
the
instrument
is
exercised/
converted.
----------------- ----------------- -------------------------- ------------------------ ------------------
C: Financial Instruments with similar economic effect
to Qualifying Financial Instruments (xv, xvi)
-----------------------------------------------------------------------------------------------
Resulting situation after the triggering transaction
-----------------------------------------------------------------------------------------------
Type of financial Exercise Expiration Exercise/ Number of voting % of voting
instrument price date Conversion rights instrument rights (xix,
(xvii) period refers to xx)
(xviii)
------------------ --------- ----------- ------------ ------------------- ----------------
Nominal Delta
------------------ --------- ----------- ------------ ------------------- -------- ------
Total (A+B+C)
------------------------------------------------------
Number of voting rights Percentage of voting rights
------------------------ ----------------------------
42,542,868 15.85%
------------------------ ----------------------------
9. Chain of controlled undertakings through which the
voting rights and/or the
financial instruments are effectively held, if applicable:
(xxi)
------------------------------------------------------------------------------
The voting rights are managed and controlled by Aviva
Investors Global Services Limited, with the following
chain of controlled undertakings:-
Aviva Investors Global Services Limited:
* Aviva plc (Parent Company)
* Aviva Group Holdings Limited (wholly owned subsidiary
of Aviva plc)
* Aviva Investors Holdings Limited (wholly owned
subsidiary of Aviva Group Holdings Limited)
* Aviva Investors Global Services Limited (wholly owned
subsidiary of Aviva Investors Holdings Limited)
Proxy Voting:
------------------------------------------------------------------------------
10. Name of the proxy holder: See Section 4
--------------------------------------------- -------------------------------
11. Number of voting rights proxy
holder will cease
to hold:
--------------------------------------------- -------------------------------
12. Date on which proxy holder will
cease to hold
voting rights:
--------------------------------------------- -------------------------------
13. Additional information: Figures are based on the
total number of voting rights
of 268,426,042 as per the
Company's Issue of Equity
Announcement of 4 January
2017.
--------------------------------------------- -------------------------------
14. Contact name: Neil Whittaker, Aviva plc
--------------------------------------------- -------------------------------
15. Contact telephone number: 01603 684420
--------------------------------------------- -------------------------------
The company news service from the London Stock Exchange
END
HOLEAEFAFDSXEFF
(END) Dow Jones Newswires
January 12, 2017 05:38 ET (10:38 GMT)
E-therapeutics (LSE:ETX)
Historical Stock Chart
From Apr 2024 to May 2024
E-therapeutics (LSE:ETX)
Historical Stock Chart
From May 2023 to May 2024
